Drug resistance profiles of Mycobacterium tuberculosis clinical isolates by genotype MTBDRplus line probe assay in Zambia: findings and implications
JAC-Antimicrobial Resistance · 03.07.2024 · 6 (4)
DOI: 10.1093/jacamr/dlae122 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, erschienen am 03.07.2024. Verfasst von Mundia Hendrix Kangongwe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Health, Chest Diseases Laboratory, Lusaka, Zambia. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The emergence of drug resistance is a threat to global tuberculosis (TB) elimination goals. This study investigated the drug resistance profiles of Mycobacterium tuberculosis (M. tuberculosis) using the Genotype MTBDRplus Line Probe Assay at the National Tuberculosis Reference Laboratory (NTRL) in Zambia.
Methods
A cross-sectional study was conducted between January 2019 and December 2020. GenoType MTBDRplus line probe assay records for patients at the NTRL were reviewed to investigate drug susceptibility profiles of M. tuberculosis isolates to rifampicin and isoniazid. Data analysis was done using Stata version 16.1.
Results
Of the 241 patient records reviewed, 77% were for females. Overall, 44% of patients were newly diagnosed with TB, 29% had TB relapse, 10% treatment after failure and 8.3% treatment after loss to follow-up. This study found that 65% of M. tuberculosis isolates were susceptible to rifampicin and isoniazid. Consequently, 35% of the isolates were resistant to rifampicin and/or isoniazid and 21.2% were multidrug-resistant (MDR). Treatment after failure [relative risk ratios (RRR) = 6.1, 95% CI: 1.691–22.011] and treatment after loss to follow-up (RRR = 7.115, 95% CI: 1.995–25.378) were significantly associated with MDR-TB. Unknown HIV status was significantly associated with isoniazid mono-resistance (RRR = 5.449, 95% CI: 1.054–28.184).
Conclusions
This study found that 65% of M. tuberculosis isolates were susceptible to rifampicin and isoniazid while 35% were resistant. Consequently, a high prevalence of MDR-TB is of public health concern. There is a need to heighten laboratory surveillance and early detection of drug-resistant TB to prevent the associated morbidity and mortality.
Autor:innen und Institutionen
- Ministry of Health, Chest Diseases Laboratory, Lusaka, Zambia.
- Institute for Basic and Biomedical Sciences, Levy Mwanawasa Medical University, Lusaka, Zambia.
- Ministry of Health, National Tuberculosis and Leprosy Programme, Lusaka, Zambia.
- Public Health, USAID-STAR Project.
- Ministry of Health, Laboratory and Pathological Services, Lusaka, Zambia.
- Epidemiology and Surveillance, Zambia National Public Health Institute, Lusaka, Zambia.
ORCID-Profile: Mundia Hendrix Kangongwe, Steward Mudenda
Zitieren
APA
Kangongwe, M. H., Mwanza, W., Mwamba, M., Mwenya, J., Muzyamba, J., Mzyece, J., Hamukale, A., Tembo, E., Nsama, D., Chimzizi, R., Mubanga, A., Tambatamba, B., Mudenda, S., & Lishimpi, K. (2024). Drug resistance profiles of Mycobacterium tuberculosis clinical isolates by genotype MTBDRplus line probe assay in Zambia: findings and implications. JAC-Antimicrobial Resistance. https://doi.org/10.1093/jacamr/dlae122
Vancouver
Kangongwe MH, Mwanza W, Mwamba M, Mwenya J, Muzyamba J, Mzyece J, et al. Drug resistance profiles of Mycobacterium tuberculosis clinical isolates by genotype MTBDRplus line probe assay in Zambia: findings and implications. JAC-Antimicrobial Resistance. 2024. doi:10.1093/jacamr/dlae122
BibTeX
@article{Kangongwe2024,
author = {Kangongwe, Mundia Hendrix and Mwanza, Winnie and Mwamba, Mutende and Mwenya, Jonathan and Muzyamba, John and Mzyece, Judith and Hamukale, Amos and Tembo, Emmanuel and Nsama, Davy and Chimzizi, Rehab and Mubanga, Angel and Tambatamba, Bushimbwa and Mudenda, Steward and Lishimpi, Kennedy},
title = {Drug resistance profiles of Mycobacterium tuberculosis clinical isolates by genotype MTBDRplus line probe assay in Zambia: findings and implications},
journal = {JAC-Antimicrobial Resistance},
year = {2024},
doi = {10.1093/jacamr/dlae122}
}
EUVIMED